1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Head and neck cancers

Pembrolizumab with lenvatinib for untreated PD-L1 positive recurrent or metastatic squamous cell head and neck cancer [ID5118]

In development [GID-TA11005] Expected publication date: TBC

  • Project information
  • Project documents

27748-Lenvatinib-with-Pembrolizumab-for-Squamous-Cell-Carcinoma-of-the-Head-and-Neck-V1.0-FEB2022-NONCONF.pdf (nihr.ac.uk)